SG10202007639SA - Compositions and methods related to multimodal therapeutic cell systems for immune indications - Google Patents
Compositions and methods related to multimodal therapeutic cell systems for immune indicationsInfo
- Publication number
- SG10202007639SA SG10202007639SA SG10202007639SA SG10202007639SA SG10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA SG 10202007639S A SG10202007639S A SG 10202007639SA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- cell systems
- methods related
- therapeutic cell
- multimodal therapeutic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277130P | 2016-01-11 | 2016-01-11 | |
| US201662359448P | 2016-07-07 | 2016-07-07 | |
| US201662370915P | 2016-08-04 | 2016-08-04 | |
| US201662420973P | 2016-11-11 | 2016-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202007639SA true SG10202007639SA (en) | 2020-09-29 |
Family
ID=57907000
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805442XA SG11201805442XA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| SG10202007639SA SG10202007639SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
| SG11201805253SA SG11201805253SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG10201913837TA SG10201913837TA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805442XA SG11201805442XA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for immune indications |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805253SA SG11201805253SA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| SG10201913837TA SG10201913837TA (en) | 2016-01-11 | 2017-01-11 | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US10456421B2 (ja) |
| EP (3) | EP3402492B1 (ja) |
| JP (5) | JP7093302B2 (ja) |
| KR (2) | KR20180095098A (ja) |
| CN (3) | CN108778298A (ja) |
| AU (2) | AU2017207736A1 (ja) |
| BR (2) | BR112018013728A2 (ja) |
| CA (2) | CA3009063A1 (ja) |
| DK (1) | DK3402491T3 (ja) |
| ES (1) | ES2907695T3 (ja) |
| HK (1) | HK1259079A1 (ja) |
| HR (1) | HRP20220147T1 (ja) |
| HU (1) | HUE057660T2 (ja) |
| IL (2) | IL260010A (ja) |
| LT (1) | LT3402491T (ja) |
| MX (2) | MX2018008515A (ja) |
| PL (1) | PL3402491T3 (ja) |
| PT (1) | PT3402491T (ja) |
| RS (1) | RS62939B1 (ja) |
| SG (4) | SG11201805442XA (ja) |
| SI (1) | SI3402491T1 (ja) |
| WO (2) | WO2017123644A1 (ja) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047507T2 (hu) | 2011-10-17 | 2020-04-28 | Massachusetts Inst Technology | Intracelluláris célbajuttatás |
| KR102304167B1 (ko) | 2013-08-16 | 2021-09-24 | 메사추세츠 인스티튜트 오브 테크놀로지 | 세포로의 선택적 물질 전달 |
| WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| DK3125927T3 (da) | 2014-04-01 | 2021-04-19 | Rubius Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulering |
| CA2964392A1 (en) | 2014-10-31 | 2016-05-06 | Massachussetts Institute Of Technology | Delivery of biomolecules to immune cells |
| CN107002089B (zh) | 2014-11-14 | 2021-09-07 | 麻省理工学院 | 化合物和组合物向细胞中的破坏和场实现的递送 |
| EP3245294A4 (en) | 2015-01-12 | 2018-05-30 | Massachusetts Institute of Technology | Gene editing through microfluidic delivery |
| CN107922911A (zh) | 2015-07-09 | 2018-04-17 | 麻省理工学院 | 将物质递送至无核细胞 |
| WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| CA3009063A1 (en) | 2016-01-11 | 2017-07-20 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| CA3052142A1 (en) | 2017-02-17 | 2018-08-23 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| KR20220124817A (ko) | 2017-08-07 | 2022-09-14 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| TW201920247A (zh) * | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 抗原呈現多肽及其使用方法 |
| CN111655292A (zh) * | 2017-12-07 | 2020-09-11 | 旗舰先锋创新V股份有限公司 | 细胞生物制品及其治疗用途 |
| RU2763798C1 (ru) * | 2017-12-23 | 2022-01-11 | Рубиус Терапьютикс, Инк. | Искусственные антигенпрезентирующие клетки и способы их применения |
| WO2019173798A1 (en) * | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| KR20210024488A (ko) * | 2018-05-24 | 2021-03-05 | 러쉬 유니버시티 메디컬 센터 | 신장 치료로 사용을 위한 icosl |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| WO2020150608A1 (en) | 2019-01-18 | 2020-07-23 | Flagship Pioneering, Inc. | Trem compositions and uses thereof |
| CN113795263A (zh) * | 2019-02-20 | 2021-12-14 | 鲁比厄斯治疗法股份有限公司 | 包含可负载抗原呈递多肽的工程化红系细胞及使用方法 |
| CN113544269A (zh) | 2019-03-04 | 2021-10-22 | 旗舰创业创新第六有限责任公司 | 环状多核糖核苷酸及其药物组合物 |
| JP2022526492A (ja) * | 2019-03-18 | 2022-05-25 | バイオ－ラッド エービーディー セロテック ゲーエムベーハー | 複数のｆｃアイソタイプ及びサブクラスに結合した抗原結合フラグメント |
| KR20210142678A (ko) | 2019-03-25 | 2021-11-25 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변형된 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 그의 용도 |
| EP3963092A1 (en) * | 2019-05-02 | 2022-03-09 | Predictive Technology Group, Inc. | Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk |
| US20220228147A1 (en) | 2019-05-31 | 2022-07-21 | Flagship Pioneering, Inc. | Uses of trem compositions to modulate trna pools |
| EP3983539A1 (en) | 2019-06-14 | 2022-04-20 | Flagship Pioneering Innovations VI, LLC | Circular rnas for cellular therapy |
| US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
| CN112195154B (zh) * | 2019-07-08 | 2024-03-29 | 江苏汇智生物科技有限公司 | 一种基因改造表达改造型pla2r受体的细胞及其应用 |
| EP4025048A2 (en) | 2019-09-05 | 2022-07-13 | Hemanext Inc. | Methods for the preservation of reagent red blood cells using carbon monoxide |
| CN114746545A (zh) * | 2019-10-18 | 2022-07-12 | 西湖生物医药科技(杭州)有限公司 | 应用人工mhc呈递特异性癌症新抗原的工程化红细胞 |
| CN115003810A (zh) | 2019-11-04 | 2022-09-02 | 旗舰创业股份有限公司 | 用于con-稀有密码子的trem组合物及相关用途 |
| EP4055169A1 (en) | 2019-11-04 | 2022-09-14 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
| WO2021155177A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof |
| WO2021155175A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Compositions for translation and methods of use thereof |
| EP4096681A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Delivery of compositions comprising circular polyribonucleotides |
| KR20220140542A (ko) * | 2020-02-07 | 2022-10-18 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 제핵 세포의 생체공학적 제조를 위한 방법 및 용도 |
| EP4153224A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Coronavirus antigen compositions and their uses |
| JP2023526423A (ja) | 2020-05-20 | 2023-06-21 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 免疫原性組成物及びその使用 |
| EP4153152A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for producing human polyclonal antibodies |
| WO2021243301A2 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| CA3180101A1 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
| US20230233514A1 (en) | 2020-06-23 | 2023-07-27 | Flagship Pioneering, Inc. | Antiviral compounds and methods of using the same |
| CA3193746A1 (en) | 2020-09-03 | 2022-03-10 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| JP2024508456A (ja) * | 2021-02-26 | 2024-02-27 | サイトナス セラピューティクス，インク． | 治療的送達のための組成物および方法 |
| WO2022197548A1 (en) | 2021-03-14 | 2022-09-22 | Rubius Therapeutics, Inc. | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| CA3232635A1 (en) | 2021-09-17 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
| WO2023064383A1 (en) * | 2021-10-12 | 2023-04-20 | Cytonus Therapeutics, Inc. | Systems and methods for manufacturing of therapeutic cells |
| TW202322826A (zh) | 2021-10-18 | 2023-06-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物及方法 |
| CA3238735A1 (en) | 2021-11-24 | 2023-06-01 | Jennifer A. Nelson | Immunogenic compositions and their uses |
| WO2023096990A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Coronavirus immunogen compositions and their uses |
| CA3238370A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
| WO2023122745A1 (en) | 2021-12-22 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| WO2023122789A1 (en) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| TW202409283A (zh) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 雙股ｄｎａ組合物及相關方法 |
| WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
| WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
| WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
| WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
| WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| WO2024059740A1 (en) * | 2022-09-14 | 2024-03-21 | Synthego Corporation | Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026290A1 (en) * | 1993-05-07 | 1994-11-24 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
| US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US20020151004A1 (en) * | 2000-07-24 | 2002-10-17 | Roger Craig | Delivery vehicles and methods for using the same |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| WO2004087876A2 (en) * | 2003-03-25 | 2004-10-14 | Valeocyte Therapies Llc | Use of red blood cells to facilitate cell activation |
| DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| NZ563263A (en) | 2005-05-17 | 2010-04-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism |
| WO2007030708A2 (en) | 2005-09-08 | 2007-03-15 | Adnexus Therapeutics, Inc. | Antimicrobial adzymes and uses thereof |
| US7462485B2 (en) | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| FR2925339B1 (fr) | 2007-12-24 | 2010-03-05 | Erytech Pharma | Medicament pour le traitement du cancer du pancreas |
| US20100316620A1 (en) | 2008-02-13 | 2010-12-16 | Vanessa Bourgeaux | Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| FR2938332B1 (fr) | 2008-11-07 | 2011-11-25 | Erytech Pharma | Test predictif de la neutralisation de l'activite asparaginase |
| FR2944106B1 (fr) | 2009-04-03 | 2012-09-28 | Erytech Pharma | Methode de dosage de l'inositol hexaphosphate (ihp). |
| ES2600932T3 (es) | 2009-10-27 | 2017-02-13 | Erytech Pharma | Composición para inducir una tolerancia inmunitaria específica |
| CN108129554A (zh) * | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| AU2013203832B2 (en) | 2012-03-13 | 2016-09-15 | Celularity Inc. | Modified erythrocyte precursor cells and uses thereof |
| SG11201405919QA (en) | 2012-03-21 | 2014-10-30 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
| CN103224957B (zh) | 2013-04-16 | 2017-08-04 | 福建三一造血技术有限公司 | 体外诱导生成含L‑ASPase II的红细胞药物的方法 |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| US10471099B2 (en) | 2013-05-10 | 2019-11-12 | Whitehead Institute For Biomedical Research | In vitro production of red blood cells with proteins comprising sortase recognition motifs |
| EP4119662A1 (en) | 2013-05-10 | 2023-01-18 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| DK3125927T3 (da) * | 2014-04-01 | 2021-04-19 | Rubius Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulering |
| WO2016183482A1 (en) * | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| EP3187190A1 (en) | 2015-12-31 | 2017-07-05 | Erytech Pharma | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |
| CA3009063A1 (en) | 2016-01-11 | 2017-07-20 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| US20190161730A1 (en) | 2016-07-07 | 2019-05-30 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
| KR20190091497A (ko) | 2016-12-02 | 2019-08-06 | 루비우스 테라퓨틱스, 아이엔씨. | 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법 |
| CA3052142A1 (en) | 2017-02-17 | 2018-08-23 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| US20190062788A1 (en) | 2017-08-22 | 2019-02-28 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| EP3703751A2 (en) | 2017-11-03 | 2020-09-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| WO2019133881A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for enginerering erythroid cells |
-
2017
- 2017-01-11 CA CA3009063A patent/CA3009063A1/en active Pending
- 2017-01-11 PL PL17701776T patent/PL3402491T3/pl unknown
- 2017-01-11 CN CN201780006086.0A patent/CN108778298A/zh active Pending
- 2017-01-11 LT LTEPPCT/US2017/013035T patent/LT3402491T/lt unknown
- 2017-01-11 PT PT177017761T patent/PT3402491T/pt unknown
- 2017-01-11 JP JP2018535844A patent/JP7093302B2/ja active Active
- 2017-01-11 CA CA3010510A patent/CA3010510A1/en active Pending
- 2017-01-11 KR KR1020187022922A patent/KR20180095098A/ko unknown
- 2017-01-11 HU HUE17701776A patent/HUE057660T2/hu unknown
- 2017-01-11 AU AU2017207736A patent/AU2017207736A1/en active Pending
- 2017-01-11 HR HRP20220147TT patent/HRP20220147T1/hr unknown
- 2017-01-11 JP JP2018535851A patent/JP2019501655A/ja active Pending
- 2017-01-11 WO PCT/US2017/013033 patent/WO2017123644A1/en active Application Filing
- 2017-01-11 RS RS20220172A patent/RS62939B1/sr unknown
- 2017-01-11 WO PCT/US2017/013035 patent/WO2017123646A1/en active Application Filing
- 2017-01-11 KR KR1020187022906A patent/KR20180095713A/ko unknown
- 2017-01-11 BR BR112018013728A patent/BR112018013728A2/pt not_active Application Discontinuation
- 2017-01-11 SG SG11201805442XA patent/SG11201805442XA/en unknown
- 2017-01-11 MX MX2018008515A patent/MX2018008515A/es unknown
- 2017-01-11 SG SG10202007639SA patent/SG10202007639SA/en unknown
- 2017-01-11 SI SI201731074T patent/SI3402491T1/sl unknown
- 2017-01-11 EP EP17703498.0A patent/EP3402492B1/en active Active
- 2017-01-11 AU AU2017207738A patent/AU2017207738A1/en active Pending
- 2017-01-11 DK DK17701776.1T patent/DK3402491T3/da active
- 2017-01-11 EP EP21216483.4A patent/EP4019026A1/en not_active Withdrawn
- 2017-01-11 CN CN202211081626.0A patent/CN115969987A/zh not_active Withdrawn
- 2017-01-11 CN CN201780006113.4A patent/CN108697733A/zh active Pending
- 2017-01-11 MX MX2018008514A patent/MX2018008514A/es unknown
- 2017-01-11 SG SG11201805253SA patent/SG11201805253SA/en unknown
- 2017-01-11 SG SG10201913837TA patent/SG10201913837TA/en unknown
- 2017-01-11 ES ES17701776T patent/ES2907695T3/es active Active
- 2017-01-11 BR BR112018013853A patent/BR112018013853A2/pt not_active Application Discontinuation
- 2017-01-11 EP EP17701776.1A patent/EP3402491B1/en active Active
- 2017-09-26 US US15/716,141 patent/US10456421B2/en not_active Expired - Fee Related
-
2018
- 2018-02-26 US US15/905,445 patent/US20180187155A1/en not_active Abandoned
- 2018-02-27 US US15/906,873 patent/US10568910B2/en not_active Expired - Fee Related
- 2018-06-13 IL IL260010A patent/IL260010A/en unknown
- 2018-06-13 IL IL259991A patent/IL259991A/en unknown
- 2018-12-03 US US16/207,568 patent/US10716811B2/en active Active
-
2019
- 2019-01-29 HK HK19101579.6A patent/HK1259079A1/zh unknown
- 2019-09-18 US US16/574,830 patent/US10517897B1/en not_active Expired - Fee Related
-
2020
- 2020-01-08 US US16/737,661 patent/US20200129556A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021031998A patent/JP2021078519A/ja active Pending
- 2021-05-13 JP JP2021081727A patent/JP2021112216A/ja active Pending
- 2021-11-17 US US17/528,422 patent/US20220072048A1/en active Pending
-
2022
- 2022-09-16 JP JP2022148073A patent/JP2022171843A/ja not_active Withdrawn
-
2023
- 2023-01-25 US US18/159,229 patent/US20230293588A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259079A1 (zh) | 與免疫適應症的多模式治療性細胞體系有關的組合物和方法 | |
| HK1258041A1 (zh) | 免疫細胞組合物和使用方法 | |
| IL266940A (en) | Preparations and methods related to cell systems for infiltrating solid tumors | |
| HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
| IL277593B (en) | Preparations and methods for the induction of life-saving t cells to 8 cd | |
| HK1244841A1 (zh) | 用於選擇性消除所關注細胞的方法和組合物 | |
| ZA201903333B (en) | Photovoltaic system and associated use | |
| EP3215495A4 (en) | Skincare formulations and regimens | |
| HK1252260A1 (zh) | 基於絲的保濕劑組合物及其方法 | |
| HK1252778A1 (zh) | 細胞擴增方法和治療組合物 | |
| IL250582A0 (en) | Compositions and methods for early screening of medical components | |
| IL259202A (en) | Modified immune cells and their use | |
| HK1256033A1 (zh) | 用於刺激免疫系統的肽 | |
| ZA201706794B (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| EP3439688A4 (en) | COMPOSITIONS AND METHODS IN CONNECTION WITH POLYCYTOTOXIC T CELLS | |
| EP3097420A4 (en) | Methods and compositions for immune dis-inhibition | |
| SG11202000811RA (en) | Methods for activating immune cells | |
| PL3277658T3 (pl) | Sposób i system do syntezy biodiesla | |
| EP3178223A4 (en) | Systems and methods to achieve interactive special effects | |
| EP3187258C0 (en) | IMPROVEMENTS IN OR RELATED TO REACTORS | |
| HK1198238A2 (en) | Solar charging system and apparatus | |
| SG11201702105QA (en) | Methods and systems for camptothecin analog synthesis | |
| GB201419559D0 (en) | Therapeutic compositions and methods | |
| AU2014901390A0 (en) | Immune cell markers and uses thereof | |
| AU2014901388A0 (en) | Immune cell markers and uses thereof |